| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 121.2MM | +1% |
| Gross Profit | 39.1MM | - |
| Cost Of Revenue | 82.2MM | -6% |
| Operating Income | -980.2MM | - |
| Operating Expenses | 1B | - |
| Net Income | -942.1MM | - |
| R&D | 58.3MM | -9% |
| G&A | 45.6MM | -35% |
| Marketing | 38MM | -15% |
| Amortization | 25.6MM | -8% |
| Interest Expense | 5.8MM | -3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Invitae Corp received court approval on Thursday to run a five-month bankruptcy sale process, allowing the genetic testing company to find a buyer and exit from Chapter 11 by late July. U.S. Bankruptcy Judge Michael Kaplan approved the Softbank-backed company's proposed bid procedures at a court hearing in Trenton, New Jersey, setting an April 10 deadline for initial bids and scheduling an auction for April 17. Invitae, which filed for bankruptcy protection on Tuesday, intends to seek court ap...
To ensure its business operates as usual, Invitae has requested court approval to fund its bankruptcy protection by using cash on hand, the company said, adding that it intends to transition into Chapter 11 without disrupting operations. The company said in a court filing that its estimated assets were in the $500 million - $1 billion range, while its liabilities were in the $1 billion - $10 billion range. Invitae, which provides genetic testing services for various diseases and cancers in and...
Invitae (OTC: NVTA), a leading medical genetics company, announced today that it is building on previous actions to manage costs and improve its business structure by filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey. Through this filing, the Company intends to safeguard its business, customers, patients and employees while working to execute an efficient and value-maximizing sale process with the support of its senior noteholders.
Sources told the Wall Street Journal a bankruptcy filing could come within weeks.
Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics company, grappling with a substantial $1.5 billion debt burden, is enlisting the expertise of restructuring advisers from FTI Consulting and legal counsel from Kirkland & Ellis to navigate its financial challenges. Amidst this financial turmoil, Invitae is actively exploring various strategic options,
San Francisco-based firm is working with Kirkland & Ellis and FTI Consulting to seek options to address $1.5 billion of debt.
Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.
Invitae shares have lost more than 80% over the past year and a half.
Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ: NTRA).
DNA testing firm Natera could pay up to $52.5 million total, and plans to move Invitae’s customers to its own tests.